Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012, Article ID 607498, 12 pages
http://dx.doi.org/10.1100/2012/607498
Research Article

Dose Effect Evaluation and Therapeutic Window of the Neuro-EPO Nasal Application for the Treatment of the Focal Ischemia Model in the Mongolian Gerbil

1National Center for Laboratory Animal Breeding, Havana, Cuba
2Histology Department, Preclinical and Basic Science Institute, Havana, Cuba
3Center of Molecular Immunology (CIM), Havana, Cuba
4Center of Research and Development of Medicaments (CIDEM), Havana, Cuba
5Institute of Neurology and Neurosurgery (INN), Havana, Cuba

Received 18 June 2011; Accepted 24 January 2012

Academic Editor: Dirk M. Hermann

Copyright © 2012 Iliana Sosa Teste et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Fisher, “The target of acute stroke therapy and neuroprotective therapeutic approaches,” Revista de Neurologia, vol. 29, no. 6, pp. 536–544, 1999. View at Google Scholar · View at Scopus
  2. M. Bacigaluppi and D. M. Hermann, “New targets of neuroprotection in ischemic stroke,” TheScientificWorldJournal, vol. 8, pp. 698–712, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. J. D. García-Salman, “Endogenous neuronal protection: an alternative approach,” Revista de Neurologia, vol. 38, no. 2, pp. 150–155, 2004. View at Google Scholar · View at Scopus
  4. L. Belayev, L. Khoutorova, W. Zhao et al., “Neuroprotective effect of darbepoetin alfa, a novel recombinant erythropoietic protein, in focal cerebral ischemia in rats,” Stroke, vol. 36, no. 5, pp. 1071–1076, 2005. View at Google Scholar · View at Scopus
  5. M. A. Catania, M. C. Marciano, A. Parisi et al., “Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils,” European Journal of Pharmacology, vol. 437, no. 3, pp. 147–150, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. A. L. Sirén, M. Fratelli, M. Brines et al., “Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 7, pp. 4044–4049, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Leist, P. Ghezzi, G. Grasso et al., “Derivatives of erythropoietin that are tissue protective but not erythropoietic,” Science, vol. 305, no. 5681, pp. 239–242, 2004. View at Publisher · View at Google Scholar
  8. Y. Sadamoto, K. Igase, M. Sakanaka et al., “Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery,” Biochemical and Biophysical Research Communications, vol. 253, no. 1, pp. 26–32, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. D. M. Hermann, “Enhancing the delivery of erythropoietin and its variants into the ischemic brain,” TheScientificWorldJournal, vol. 9, pp. 967–969, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. L. Sirén, F. Knerlich, W. Poser, C. H. Gleiter, W. Brück, and H. Ehrenreich, “Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain,” Acta Neuropathologica, vol. 101, no. 3, pp. 271–276, 2001. View at Google Scholar · View at Scopus
  11. H. Ehrenreich, R. Nau, C. Dembowski et al., “Endothelin B receptor deficiency is associated with an increased rate of neuronal apoptosis in the dentate gyrus,” Neuroscience, vol. 95, no. 4, pp. 993–1001, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Brines and A. Cerami, “Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response,” Journal of Internal Medicine, vol. 264, no. 5, pp. 405–432, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Muñoz-Cernuda, R. León-Rodríguez, J. García-Rodríguez et al., “Formulaciones nasales de EPOhr con bajo contenido de ácido siálico para el tratamiento de enfermedades del Sistema Nervioso Central,” (20050138) Patent Cuba, 7–22, 2005.
  14. A. Cerami, M. L. Brines, P. Ghezzi, and C. J. Cerami, “Effects of epoetin alfa on the central nervous system,” Seminars in Oncology, vol. 28, supplement 8, pp. 66–70, 2001. View at Google Scholar
  15. A. Cerami, M. Brines, P. Ghezzi, C. Cerami, and L. M. Itri, “Neuroprotective properties of epoetin alfa,” Nephrology Dialysis Transplantation, vol. 17, no. 1, pp. 8–12, 2002. View at Google Scholar · View at Scopus
  16. Y. Li, Z. Lu, C. L. Keogh, S. P. Yu, and L. Wei, “Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice,” Journal of Cerebral Blood Flow & Metabolism, vol. 27, no. 5, pp. 1043–1054, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. L. Sirén, T. Faßhauer, C. Bartels, and H. Ehrenreich, “Therapeutic potential of erythropoietin and its structural or functional variants in the nervous system,” Neurotherapeutics, vol. 6, no. 1, pp. 108–127, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Dame, S. E. Juul, and R. D. Christensen, “The biology of erythropoietin in the central nervous system and its neurotrophic and neuroprotective potential,” Biology of the Neonate, vol. 79, no. 3-4, pp. 228–235, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. A. V. Kabanov and E. V. Batrakova, “New technologies for drug delivery across the blood brain barrier,” Current Pharmaceutical Design, vol. 10, no. 12, pp. 1355–1363, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. W. A. Banks, “Are the extracellular pathways a conduit for the delivery of therapeutics to the brain?” Current Pharmaceutical Design, vol. 10, no. 12, pp. 1365–1370, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Kalialis and N. Olsen, “Erythropoietin—a new therapy in cerebral ischemia?” Ugeskr Laeger, vol. 165, no. 24, pp. 2477–2481, 2003. View at Google Scholar
  22. H. H. Marti, “Erythropoietin gene expression in human, monkey and murine brain,” European Journal of Neuroscience, vol. 8, no. 4, pp. 666–676, 1996. View at Publisher · View at Google Scholar
  23. W. A. Banks, M. J. During, and M. L. Niehoff, “Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration,” Journal of Pharmacology and Experimental Therapeutics, vol. 309, no. 2, pp. 469–475, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. S. Erbayraktar and O. Yilmaz, “Erythropoietin is a multifunctional tissue-protective cytokine,” Current Hematology Reports, vol. 2, no. 6, pp. 465–470, 2003. View at Google Scholar
  25. A. Nagai, E. Nakagawa, H. B. Choi, K. Hatori, S. Kobayashi, and S. U. Kim, “Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia, and oligodendrocytes grown in culture,” Journal of Neuropathology and Experimental Neurology, vol. 60, no. 4, pp. 386–392, 2001. View at Google Scholar · View at Scopus
  26. C. Wiessner, P. R. Allegrini, D. Ekatodramis, U. R. Jewell, T. Stallmach, and M. Gassmann, “Increased cerebral infarct volumes in polyglobulic mice overexpressing erythropoietin,” Journal of Cerebral Blood Flow & Metabolism, vol. 21, no. 7, pp. 857–864, 2001. View at Google Scholar · View at Scopus
  27. W. Jelkmann, “Molecular biology of erythropoietin,” Internal Medicine, vol. 43, no. 8, pp. 649–659, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. P. Yu, Q. Q. Xu, Q. Zhang, W. P. Zhang, L. H. Zhang, and E. Q. Wei, “Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia,” Neuroscience Letters, vol. 387, no. 1, pp. 5–10, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Mostacero, “Neurotoxicity, neuroprotection and therapeutic window in the cerebral ischemia,” Revista de Neurologia, vol. 29, no. 6, pp. 513–514, 1999. View at Google Scholar · View at Scopus
  30. S. Cotena, O. Piazza, and R. Tufano, “The use of erythtropoietin in cerebral diseases,” Panminerva Medica, vol. 50, no. 2, pp. 185–192, 2008. View at Google Scholar · View at Scopus
  31. Consejo Canadiense de Protección de los animales, “Guidelines for Breeding and Care of Laboratory Animals,” World Health Organization and Institucional Council for Laboratory Animals Science (ICLAS), 1998.
  32. I. Sosa Testé, J. C. García Rodríguez, J. D. García Salman et al., “Intranasal administration OF recombinant human erythropoietin exerts neuroprotective effects on post-ischemic brain injury in mongolian gerbils,” PharmacologyOnline, vol. 1, pp. 100–112, 2006. View at Google Scholar
  33. J. D. Butterfield and C. P. McGraw, “Effect of DPPD (diphenyl-para-phenylenediamine) on stroke and cerebral edema in gerbils,” Stroke, vol. 9, no. 5, pp. 480–483, 1978. View at Google Scholar · View at Scopus
  34. P. Lawner, J. Laurent, and F. Simeone, “Attenuation of ischemic brain edema by pentobarbital after carotid ligation in the gerbil,” Stroke, vol. 10, no. 6, pp. 644–647, 1979. View at Google Scholar · View at Scopus
  35. Y. Rodríguez Cruz, Y. Mengana Támos, A. Muñoz Cernuda et al., “Treatment with nasal neuro-EPO improves the neurological, cognitive, and histological state in a gerbil model of focal ischemia,” TheScientificWorldJournal, vol. 10, pp. 2288–2300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. D. Agnello, P. Bigini, P. Villa et al., “Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis,” Brain Research, vol. 952, no. 1, pp. 128–134, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Erbayraktar, G. Grasso, A. Sfacteria et al., “Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6741–6746, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Fisher, “Recommendations for standards regarding preclinical neuroprotective and restorative drug development,” Stroke, vol. 30, no. 12, pp. 2752–2758, 1999. View at Publisher · View at Google Scholar
  39. K. A. Hossmann, “Pathophysiology and therapy of experimental stroke,” Cellular and Molecular Neurobiology, vol. 26, no. 7-8, pp. 1057–1083, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. R. J. Traystman, “Animal models of focal and global cerebral ischemia,” ILAR Journal, vol. 44, no. 2, pp. 85–95, 2003. View at Google Scholar · View at Scopus
  41. G. P. Pelliccioli, C. Gambelunghe, P. F. Ottaviano, S. Iannaccone, and M. V. Ambrosini, “Variable response of the Mongolian gerbil to unilateral carotid occlusion: magnetic resonance imaging and neuropathological characterization,” The Italian Journal of Neurological Sciences, vol. 16, no. 7, pp. 517–526, 1995. View at Publisher · View at Google Scholar · View at Scopus
  42. L. I. Somova, M. A. Gregory, and E. N. Nxumalo, “Mongolian gerbil (Meriones unguiculatus) as a model of cerebral infarction for testing new therapeutic agents,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 22, no. 4, pp. 203–210, 2000. View at Google Scholar · View at Scopus
  43. M. Babcock, D. A. Baker, and R. Lovec, “Locomotor activity in the ischemic gerbil,” Brain Research, vol. 625, no. 2, pp. 351–354, 1993. View at Publisher · View at Google Scholar · View at Scopus
  44. H. M. Payan and J. R. Conard, “Carotid ligation in gerbils. Influence of age, sex, and gonads,” Stroke, vol. 8, no. 2, pp. 194–196, 1977. View at Google Scholar · View at Scopus
  45. L. Torup and M. Leist, “Development of non-erythropoietic erythropoietin variants for neuroprotection,” in Erythropoietin and the Nervous System, Springer, New York, NY, USA, 2006. View at Google Scholar
  46. S. M. Graham, L. D. McCullough, and S. J. Murphy, “Animal models of ischemic stroke: balancing experimental aims and animal care,” Comparative Medicine, vol. 54, no. 5, pp. 486–496, 2004. View at Google Scholar · View at Scopus
  47. S. E. Juul, D. K. Anderson, Y. Li, and R. D. Christensen, “Erythropoietin and erythropoietin receptor in the developing human central nervous system,” Pediatric Research, vol. 43, no. 1, pp. 40–49, 1998. View at Google Scholar · View at Scopus
  48. M. Chopp, Y. Li, and J. Zhang, “Plasticity and remodeling of brain,” Journal of the Neurological Sciences, vol. 265, no. 1-2, pp. 97–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. B. Boroojerdi, U. Ziemann, R. Chen, C. M. Bütefisch, and L. G. Cohen, “Mechanisms underlying human motor system plasticity,” Muscle and Nerve, vol. 24, no. 5, pp. 602–613, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. H. Ehrenreich, C. Bartels, D. Sargin, S. Stawicki, and H. Krampe, “Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition,” Journal of Renal Nutrition, vol. 18, no. 1, pp. 146–153, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. T. Kirino, A. Tamura, and K. Sano, “Delayed neuronal death in the rat hippocampus following transient forebrain ischemia,” Acta Neuropathologica, vol. 64, no. 2, pp. 139–147, 1984. View at Google Scholar · View at Scopus
  52. T. Kirino and K. Sano, “Fine structural nature of delayed neuronal death following ischemia in the gerbil hippocampus,” Acta Neuropathologica, vol. 62, no. 3, pp. 209–218, 1984. View at Google Scholar · View at Scopus
  53. F. Colbourne, H. Li, and A. M. Buchan, “Continuing postischemic neuronal death in CA1: influence of ischemia duration and cytoprotective doses of NBQX and SNX-111 in rats,” Stroke, vol. 30, no. 3, pp. 662–668, 1999. View at Google Scholar · View at Scopus
  54. J. H. Halsey, N. F. Capra, and R. S. McFarland, “Use of hydrogen for measurement of regional cerebral blood flow: problem of intercompartmental diffusion,” Stroke, vol. 8, no. 3, pp. 351–357, 1977. View at Google Scholar
  55. Y. Xiong, A. Mahmood, C. Qu et al., “Erythropoietin improves histological and functional outcomes after traumatic brain injury in mice in the absence of the neural erythropoietin receptor,” Journal of Neurotrauma, vol. 27, no. 1, pp. 205–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. P. E. Sanchez, R. P. Fares, J. J. Risso et al., “Optimal neuroprotection by erythropoietin requires elevated expression of its receptor in neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 24, pp. 9848–9853, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Gao, Y. Mengana, Y. R. Cruz et al., “Different expression patterns of ngb and epor in the cerebral cortex and hippocampus revealed distinctive therapeutic effects of intranasal delivery of neuro-epo for ischemic insults to the gerbil brain,” Journal of Histochemistry and Cytochemistry, vol. 59, no. 2, pp. 214–227, 2011. View at Publisher · View at Google Scholar
  58. M. Bernaudin, H. H. Marti, S. Roussel et al., “A potential role for erythropoietin in focal permanent cerebral ischemia in mice,” Journal of Cerebral Blood Flow & Metabolism, vol. 19, no. 6, pp. 643–651, 1999. View at Google Scholar · View at Scopus
  59. M. Fisher and B. Bastan, “Treating acute ischemic stroke,” Current Opinion in Drug Discovery and Development, vol. 11, no. 5, pp. 626–632, 2008. View at Google Scholar · View at Scopus
  60. R. G. Thorne, C. R. Emory, T. A. Ala, and W. H. Frey, “Quantitative analysis of the olfactory pathway for drug delivery to the brain,” Brain Research, vol. 692, no. 1-2, pp. 278–282, 1995. View at Publisher · View at Google Scholar · View at Scopus
  61. K. A. Hossmann, “Experimental models for the investigation of brain ischemia,” Cardiovascular Research, vol. 39, no. 1, pp. 106–120, 1998. View at Publisher · View at Google Scholar · View at Scopus
  62. M. D. Ginsberg, “Neuroprotection for ischemic stroke: past, present and future,” Neuropharmacology, vol. 55, no. 3, pp. 363–389, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. P. A. Lapchak and D. M. Araujo, “Advances in ischemic stroke treatment: neuroprotective and combination therapies,” Expert Opinion on Emerging Drugs, vol. 12, no. 1, pp. 97–112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. G. Micieli, S. Marcheselli, and P. A. Tosi, “Safety and efficacy of alteplase in the treatment of acute ischemic stroke,” Vascular Health and Risk Management, vol. 5, pp. 397–409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Dame and H. Fahnenstich, “Don't give up on erythropoietin as a neuroprotective agent,” Pediatrics, vol. 116, no. 2, pp. 521–522, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. P. T. Tsai, J. J. Ohab, N. Kertesz et al., “A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery,” Journal of Neuroscience, vol. 26, no. 4, pp. 1269–1274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Wang, Z. Zhang, Y. Wang, R. Zhang, and M. Chopp, “Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats,” Stroke, vol. 35, no. 7, pp. 1732–1737, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. P. Villa, J. Van Beek, A. K. Larsen et al., “Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives,” Journal of Cerebral Blood Flow & Metabolism, vol. 27, no. 3, pp. 552–563, 2007. View at Publisher · View at Google Scholar
  69. J. C. G. Rodríguez and I. S. Teste, “The nasal route as a potential pathway for delivery of erythropoietin in the treatment of acute ischemic stroke in humans,” TheScientificWorldJournal, vol. 9, pp. 970–981, 2009. View at Publisher · View at Google Scholar · View at Scopus
  70. J. Minnerup, J. Heidrich, A. Rogalewski, W. R. Schäbitz, and J. Wellmann, “The efficacy of erythropoietin and its analogues in animal stroke models: a meta-analysis,” Stroke, vol. 40, no. 9, pp. 3113–3120, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. M. Fantacci, P. Bianciardi, A. Caretti et al., “Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 46, pp. 17531–17536, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. F. Fiordaliso, S. Chimenti, L. Staszewsky et al., “A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 6, pp. 2046–2051, 2005. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Mintorovitch, G. Y. Yang, H. Shimizu, J. Kucharczyk, P. H. Chan, and P. R. Weinstein, “Diffusion-weighted magnetic resonance imaging of acute focal cerebral ischemia: comparison of signal intensity with changes in brain water and Na+,K+-ATPase activity,” Journal of Cerebral Blood Flow & Metabolism, vol. 14, no. 2, pp. 332–336, 1994. View at Google Scholar